ADC opens second R&D Lab

ADC Bio has commissioned a second dedicated R&D lab to meet customer demand for technical services to support ADCs in pre-clinical development. Surging interest in ADC anti-cancer drugs sees over 150 in pre-clinical development and nearly 50 in clinical trials.

Coming on stream earlier this year, emphasis in the latest £100,000 lab expansion is expanding service capabilities in payload-linker customisation and downstream bio-conjugation.

The company is one of just a handful of independent technical service providers in the fastest growing sector of oncology therapies.

ADC Bio now has three labs at St Asaph, with a total footprint of 210m and 12 science staff, including two additional chemistry staff focusing on payload-linker design. Overall this represents a 100% growth for the science teams in less than two years.

The third lab is dedicated to continuing development and commercialisation of the company’s core “Lock-Release” bio-conjugation technology that enables development of optimal ADC formats and expedites development of clinical ADC candidates.

The development mirrors continuing acceleration in the company’s technical services business and is the second significant increase in lab capabilities since 2012.

Previously, growing demand for its R&D services triggered a £125,000 lab expansion and matching staff additions in April 2013 – with further expansion in 2014.

ADC Bio has 10 worldwide repeat customers, won its 80th project during Q1 and was ahead-of-forecast for FY 2014/15, which ended in June.

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.